alexa Seprafilm Mediated Immune Response Mimic Danger Signal: A Pilot Study in Ovarian Cancer Cases | OMICS International
ISSN: 2155-9619
Journal of Nuclear Medicine & Radiation Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Seprafilm Mediated Immune Response Mimic Danger Signal: A Pilot Study in Ovarian Cancer Cases

Tzu-Hsuan Chin1, Hsiu-Huei Peng1, Cheng-Tao Lin1,2,3*

1Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Linkou Medical Center, Taoyuan, Taiwan

2Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Linkou Medical Center, Taoyuan, Taiwan

3Chang Gung Gynecological Oncology Cancer Center, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan

*Corresponding Author:
Cheng-Tao Lin
Department of Obstetrics and Gynecology
Chang Gung Memorial Hospital, Linkou Medical Center
Chang Gung University College of Medicine, 5, Fu-Hsin Street
Kwei Shan Taoyuan, Taiwan
Tel: 886-3-3281200
E-mail: [email protected]

Received date: September 20, 2016; Accepted date: September 23, 2016; Published date: September 30, 2016

Citation: Tzu-Hsuan C, Hsiu-Huei P, Cheng-Tao L (2016) Seprafilm Mediated Immune Response Mimic Danger Signal: A Pilot Study in Ovarian Cancer Cases. J Nucl Med Radiat Ther 7:305. doi: 10.4172/2155-9619.1000305

Copyright: © 2016 Tzu-Hsuan C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Nuclear Medicine & Radiation Therapy

Abstract

Danger signal was first proposed in 1994. In response to danger signal, dendritic cells, as the director of the T-cell immune system, would be matured and further enhance T-cell response. Hyaluronan had been reported as one of endogenous danger signals. Because of Seprafilm (most used for preventing post-operation adhesion) is also an hyaluronate-based agent, so we choose Seprafilm as our “candidate” of emerging danger signal to increasing T-cell response. We perform a pilot study in 10 ovarian cancer patients to compare the immune risk profiles between cases using Seprafilm (5 cases) and not using Seprafilm (5 cases). We found that there is no statistical difference on the immune risk profiles between two groups. However, a trend of increased CD4 in Seprafilm group was noted, indicating that Seprafilm might be an optional agent mimic danger signal. The potential value of Seprafilm to augment host immunosurveillance to improve survival rate in cancer patients is unknown, further study is needed to clarify the possibility of clinical applications.

Keywords

Seprafilm; Immune; Ovarian cancer

Introduction

Most of the cases of ovarian cancer are diagnosed as advanced stage. Although there is 70% to 80% of complete remission after standard treatment (including debulking surgery, chemotherapy and radiotherapy), they still face 60% to 70% chance of disease relapse. Once relapse, they suffer from detrimental outcome following first-line treatment [1]. So we urgently need better therapy, and how to augment the host immunosurveillance may be the way forward.

As we know, in response to danger signal, dendritic cells would be matured and further enhance T-cell response. Hyaluronan had been reported as one of endogenous danger signals, so we choose Seprafilm as our “candidate” of emerging danger signal to increasing T-cell response in ovarian cancer patients.

Materials and Methods

From 2009 to 2010, we collected 10 cases of ovarian cancer patients at Linkou Chang Gung Memorial Hospital, Taiwan. This study was approved by the Institutional Review Board of the Chang Gung Memorial Hospital, Taiwan (100-3902A3 & 103-4220C), and the informed consent are obtained from all the patients. The characteristics of the 10 patients are listed in Table 1. All these ovarian cancer patients received surgery. Among the 10 cases, five cases had Seprafilm (15 cm × 13 cm, genzyme) placed during surgery, and the other five cases don’t have Seprafilm placed during surgery.

  Seprafilm Non-Seprafilm
Age Range 23-61 50-57
Median 49.4 53.8
Pathology Mucinous 1 1
Serous 2 3
Papillary serous 1 0
Endometrioid 1 0
Mixed pattern 0 1
Stage I/II 1 0
III/IV 4 5
Surgery Debulking 1 3
Fertility preserving 2 0
Inoperable 1 1
Second look 1 1
Survival >5 years 3 0
Median survival (year) 3.8 3

Table 1: Patient characteristics.

Considering the natural absorption of Seprafilm (that is, Seprafilm will form a gel-like fluid within 24 h to 48 h, and slowly resorbed within 7 days), we check immune risk profiles (IRP) before the operation, and immune risk profiles one week later after the operation. The immune risk profiles we checked included CD3 (common T cells), CD19 (B cells), CD4, CD8, CD40, CD28, CD154, NK, and immunoregulatory CD25 and CD11b, etc. The statistic difference of selected immune risk profiles (CD4, CD8, NK, CD11b, CD28) between two groups of patients were analyzed by Chi-square.

We also check some suspected markers of other danger signals before operation and one week after operation. Uric acid was chosen as classic danger signal. CRP, LDH and d-dimer were chosen as marker to monitor homeostatic danger signal.

Results

Characteristics of the patients

The characteristics of the 10 cases of ovarian cancer is listed in Table 1. In Seprafilm group (SG), the median age was 49.4 y/o and only one case was stage Ic ovarian cancer, the other 4 cases were all advanced stage. In non-Seprafilm group (NSG), the median age was 53.8 y/o and all of the 5 cases has advanced stage ovarian cancer. In 5-year-survival, 3 patients in Seprafilm group were over 5 years and none in non- Seprafilm group had survival over 5 years.

Immune risk profiles

The comparison of the immune risk profiles (CD4, CD8, NK, CD11b, CD28) before operation and one week after operation in 5 cases of Seprafilm group (SG) and 5 cases of non-Seprafilm group (NSG) are shown in Table 2. Elevated CD4 in 80% cases (4/5) and elevated NK in 60% cases (3/5) were noted in Seprafilm group. In the non-Seprafilm group, elevated CD4 in 40% cases (2/5) and elevated NK in 20% cases (1/5) were noted, respectively. We observed that CD4 had an increasing trend in Seprafilm group compared to non-Seprafilm group, although it doesn’t has statistical significance. Moreover, we find out CD4 helper T cells to be elevated 5.1 % (range 2.4% to 9%) in 4 cases of Seprafilm group one week after operation, compared to 4.6% (range 2% to 7.2%) in three cases of non-Seprafilm group.

Case number ofelevated immune profile Seprafilm Non-seprafilm P value
CD4 4 2 0.5186
CD8 4 4 1
CD4/CD8 3 2 0.5271
NK 3 1 0.5186
CD11b 3 3 1
CD28 3 3 1

Table 2: Compare immune profile between Seprafilm group(SG) and non-Seprafilm group(NSG).

CD28 elevation had same cases in both groups, that is, 60% (3/5) in Seprafilm group and 60% (3/5) in non-Seprafilm group. Also, we find out less CD28 percentage to elevate 5.1% (range 0.5% to 10.3%) in Seprafilm group than 7.6% (range 7.4% to 8.6%) in non-Seprafilm group. These findings indicate that operative insertion of Seprafilm may rendered host’s immune cells polarized less Th2 status to enhance more Th1 status.

Uric acid, CRP, LDH and d-dimer

The result of uric acid, CRP, LDH and d-dimer before operation and one week after operation in 5 cases of Seprafilm group (SG) and 5 cases of non-Seprafilm group (NSG) are shown in Table 3.1-3.4. We found elevated uric acid in all patients who survived over 5 years (Table 3.1). While, CRP and LDH couldn’t found the relation with prognosis in our limited cases (Table 3.2 and 3.3). D-dimer elevation were noted in all patient in non-Seprafilm group (Table 3.4).

  UA before operation UA after operation  
S1 5.6 8.6 +3
S2 5 6.3 +1.3
S3 5 4.6 -0.4
S4 3.1 6.3 +3.2
S5 3 3.6 +0.6
NS1 6.6 9.6 +3
NS2 3.5 4.7 +1.2
NS3 3.8 9.2 +5.4
NS4 5.7 NA NA
NS5 8 3.2 -4.8

Table 3.1: Compare uric acid change between SG and NSG.

  CRP before operation CRP after operation  
S1 0.58 3.89 +3.31
S2 20.9 161.26 +140.36
S3 NA 33.52 NA
S4 87.95 18.36 -69.59
S5 2.01 9.04 +7.03
NS1 357.87 NA NA
NS2 114.35 37.58 -76.77
NS3 41.03 1.85 -39.18
NS4 8.05 90.43 +82.38
NS5 28.89 38.26 +9.38

Table 3.2: Compare C-reactive protein(CRP) change between SG and NSG.

  LDH before operation LDH after operation  
S1 NA 529 NA
S2 278 301 +23
S3 359 335 -24
S4 271 389 +118
S5 437 251 -186
NS1 1529 896 -633
NS2 616 332 -284
NS3 265 240 -25
NS4 136 NA NA
NS5 450 414 -36

Table 3.3: Compare lactic dehydrogenase(LDH) change between SG and NSG.

  D-dimer before operation D-dimer after operation  
S1 204 1057 +853
S2 3636 2130 -1506
S3 2505 >10000 > +7495
S4 >10000 4639 < -5361
S5 481 3302 +2821
NS1 8929 >10000 > +1071
NS2 2943 3940 +997
NS3 3807 4270 +463
NS4 4103 >10000 > +5897
NS5 2415 6083 +3668

Table 3.4: Compare D-dimer change between SG and NSG.

Discussion

Several studies had shown that the immune system plays an important role in controlling and elimination of cancer. T-cell rich ovarian tumors were associated with improved 5-year overall survival relative to T-cell poor ovarian tumors (38.0% vs. 4.5%) [2]. In general, the immunocompromised patients had more risks of cancer relapse following conventional therapy. The existence of local residual cancer cells resulted from escaping recognition of host immunosurveillance. Therefore, improving existing host immune systemic scenarios through immunomodulatory adjuvants was needed.

Harnessing immune cells switched Th1/Th2 responses in relapse of ovarian cancer that all signals were needed [3]. After conventional optimal debulking operation, we tried to find a way to trigger antigenpresenting cells such as dendtritic cells, macrophages and B cells which would generate and/or amplify host immunosurveillance. The final goal is to improve overall survival, long-term survival rate and prevent relapse of ovarian cancer.

The term “danger signal” was proposed in 1994. It’s an alarm signal sent by dead, damaged or invaded cell, which included exogenous and endogenous origin. In response to danger signal, dendritic cells “the director of the T-cell immune system” would be matured and further enhance T-cell response. For naïve T-cell activation, the danger signal mimic signal 0 to facilitate dendritic cells. Based on the above theory, we hoped to find a substance we could apply on increasing T-cell response. In the past, hyaluronan had been reported as one of endogenous danger signals [4,5]. Seprafilm which is a hyaluronate-based agent was used for preventing postoperative adhesion. The Seprafilm hydrates to form a gel-like fluid within 24 h to 48 h, and is slowly resorbed within 7 days [6]. Our hypothesis is that additional Seprafilm placed during operation could mimic danger signal and induce intraperitoneal immune response. If further proved, it might be an additional management option for ovarian cancer patients, which had 5-year-survival rate around 50% and even worse in advanced stage [7].

In our study, we observed that CD4 had an increasing trend in Seprafilm group compared to non-Seprafilm group, although it doesn’t has statistical significance. The results indicate that Seprafilm may mimic danger signal to activate more dendritic cells. Later, matured DCs could be initiators of immune responses like stimulation of quiescent, naive and memory, B and T lymphocytes [8-11]. Effector T-cell such as cytotoxic T-cell had role in destroying cancer cell. Memory effector cell could play a part in protecting our body from cancer cell recurrence. Naïve T cells are activated in secondary lymphoid tissue by dendritic cells presenting cognate antigen and providing co-stimulation. In all these effector T cells, approximately 90% to 95% will die over 1-2 weeks. Other 5% to 10% of the antigen-specific T-cell population survives and maintained indefinitely. That means, few activated T cells generate fewer effector T cells, much fewer memory T cells. Based on this, if we can activate more dendritic cells, we will activate more effector T cells and memory T cells (Figure 1).

nuclear-medicine-radiation-danger-signal

Figure 1: The danger signal can induce immature dendritic cell to mature dendritic cell.

In the previous study, Ruiz-Perez et al. had reported that Seprafilm as a immunomodulator in sepsis (animal model) [12-14]. It had showed a trend in suppression of T-cell proliferation and reduction in their ability to release IL-2 and TNF-a. Our study shows similar result, that is, signal 2 CD28 had less elevate mean of immune cells index in Seprafilm group than non-Seprafilm group.

As we know, there are three kinds of danger signals. First, classic danger signal, refer to pathogen-associated molecular patterns (PAMPs) or directly derived from tissue injury damage-associated molecular patterns (DAMPs), or secreted by activated immune cells. Second, emerging danger signal, include inorganic materials and man-made technologies. Third, homeostatic danger signal, represent perturbations in tissue steady state resulting inflammation. In our study, Seprafilm could be regarded as our “candidate” of emerging danger signal. We also collected uric acid, CRP, LDH and d-dimer as suspected clinical danger signal marker. We found elevated uric acid in all patients who survived over 5 years (Table 3.1), and D-dimer elevation in all patient in non-Seprafilm group (Table 3.4). We supposed uric acid could be regarded as clinical monitor of danger signal, and elevated d-dimer may relate to poor prognosis.

In conclusion, we believed that Seprafilm could be an optional agent mimic danger signal. Reliable clinical markers to monitor danger signal can assist in monitoring efficacy of immunotherapy, and uric acid may be a useful marker. Further studies with larger sample size and cytokine profiles were needed, which is important for improving survival rate and prevent cancer relapse.

Acknowledgments

The study was supported by grants CRRPG3C0911, CRRPG3D0051-3, CMRPG3F0251 (Cheng-Tao Lin), which was provided by Chang Gung Memorial Hospital (Taoyuan, Taiwan).

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 8195
  • [From(publication date):
    September-2016 - Dec 14, 2017]
  • Breakdown by view type
  • HTML page views : 8129
  • PDF downloads : 66
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]ne.com

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version